GNSN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Stronger Balance SheetThe substantial reduction in debt alongside higher equity improves Genus’s financial resilience and reduces pressure from financing obligations. A stronger capital structure should provide greater flexibility to sustain research investment, support customers, and manage livestock-market volatility over the coming quarters.
Improved Cash GenerationHigher operating and free cash flow strengthens Genus’s ability to fund operations and strategic investment internally. This is especially supportive because cash generation can reinforce balance-sheet improvement, although the company’s longer-term conversion history remains uneven and merits monitoring.
Recurring Genetics Business With Proprietary R&DGenus operates in a specialized genetics market where customers repeatedly purchase breeding products and related services to maintain and improve herds. Long-term relationships, performance data, reproductive support, and proprietary R&D can reinforce customer retention and differentiate its offerings.
Bears Say
Recent Revenue ContractionThe recent lack of top-line growth indicates that Genus has not consistently expanded demand or production volumes across its businesses. Continued revenue stagnation would limit operating leverage, constrain reinvestment capacity, and make future profit improvement more dependent on costs or non-sales factors.
Volatile And Lower-quality ProfitabilityProfit volatility makes it harder to assess Genus’s sustainable earnings power and weakens confidence in using the latest profit result as a recurring baseline. The sharp income increase without revenue growth suggests that underlying operating performance may not have improved proportionately.
Uneven Cash-flow Conversion And ReturnsAlthough the latest cash result improved, prior negative or weak free cash flow shows that earnings have not converted consistently into funds available for reinvestment or distribution. Weaker recent return on equity also indicates that the healthier capital structure has not yet produced consistently strong profitability.
Genus plc News
GNSN FAQ
What was Genus PLC’s price range in the past 12 months?
Currently, no data Available
What is Genus PLC’s market cap?
Genus PLC’s market cap is $32.98B.
When is Genus PLC’s upcoming earnings report date?
Genus PLC’s upcoming earnings report date is Feb 25, 2027 which is in 164 days.
How were Genus PLC’s earnings last quarter?
Genus PLC released its earnings results on Sep 10, 2026. The company reported $88.138 earnings per share for the quarter.
Is Genus PLC overvalued?
According to Wall Street analysts Genus PLC’s price is currently Undervalued.
Does Genus PLC pay dividends?
Genus PLC does not currently pay dividends.
What is Genus PLC’s EPS estimate?
Genus PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genus PLC have?
Genus PLC has 66,540,760 shares outstanding.
What happened to Genus PLC’s price movement after its last earnings report?
Genus PLC reported an EPS of $88.138 in its last earnings report. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Genus PLC?
Currently, no hedge funds are holding shares in MX:GNSN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genus plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$643.25 (― Upside)
$643.25 (― Upside)
Blogger Sentiment
Bullish
MX:GNSN Sentiment 100%
Sector Average 61%
Sector Average 61%
Insider Transactions
Bought Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.18%
12-Months-Change
Fundamentals
Return on Equity
1.60%
Trailing 12-Months
Asset Growth
13.27%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Genus PLC
Genus plc is a global animal genetics company with operations spanning North America, Latin America, the UK, continental Europe, the Middle East, Russia, Africa, and Asia. The business is divided into three key segments: Genus PIC, Genus ABS, and Genus Research and Development. Under its PIC brand, the company provides breeding stock, including sows, boars, and semen, to develop pigs with specific characteristics optimized for pork production. Similarly, for cattle, its ABS, Genus, and Bovec brands offer bull semen and embryos designed to produce calves with advantageous traits for either milk or beef output. Farmers also benefit from a range of specialized technical services, such as semen sexing and reproductive solutions. Genus plc is also strategically collaborating with Beijing Capital Agribusiness Co. Ltd on the research, development, and regulatory approval of porcine reproductive and respiratory syndrome virus (PRRSV)-resistant pigs in China. The company was established in 1994 and is based in Basingstoke, United Kingdom.